Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab + Cetuximab + Platinum in SCCHN
NCT02633800Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2015
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of patritumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Daiichi Sankyo Co., Ltd.. Started Dec 2015; status: terminated.
02
Drugs
patritumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02633800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633800.